Skip to main content

Advertisement

Table 1 Basic characteristics of the patient cohort with primary glioblastoma

From: Serum microRNA profiling in patients with glioblastoma: a survival analysis

Variables Set one (N = 40) Set two (N = 66) Combined set (N = 106)
Vital status
 Alive 20 (50%) 53 (84.1%) 73 (68.9%)
 Dead 20 (50%) 13 (19.7%) 33 (31.1%)
Sex
 Female 15 (37.5%) 25 (37.9%) 40 (37.7%)
 Male 25(62.5%) 41 (62.1%) 66 (62.3%)
Ethnicity
 White 37 (92.5%) 63 (95.4%) 100 (94.3%)
 Non-White 3 (7.5%) 3 (4.54%) 6 (5.7%)
Smoking history
 Ever a smoker 18 (45.0%) 30 (45.5%) 48 (45.3%)
 Never a smoker 17 9(42.5%) 29 (43.9%) 46 (43.4%)
 Unknown 5 (12.5%) 5 (7.6%) 10 (9.4%)
Recurrence/progression
 Yes 26 (65.0%) 42 (63.6%) 68 (64.8%)
 No 14 (35.0%) 23 (36.4%) 37 (35.2%)
KPS score
 100 8 (20.0%) 15 (22.7%) 23 (21.7%)
 90 20 (50.0%) 27 (40.9%) 47 (44.3%)
 80 5 (12.5%) 14 (21.2%) 19 (17.9%)
  < 80 7 (17.5%) 10 (15.2%) 17 (16.0%)
Timing of blood draw
 Newly diagnosed, post surgery 18 (45.0%) 31 (47.0%) 49 (46.2%)
 Newly diagnosed, immediately post or during radiation therapy 0 (0.0%) 3 (4.5%) 3 (2.8%)
 Newly diagnosed, immediately post or during adjuvant chemotherapy 12 (30.0%) 14 (21.2%) 26 (24.5%)
 Newly diagnosed, immediately post or during chemoradiation 10 (25.0%) 18 (27.3%) 28 (26.4%)
IDH1 mutation status
 Negative 24 (60.0%) 34 (51.5%) 58 (54.7%)
 Positive 3 (7.5%) 6 (9.1%) 9 (8.5%)
 unknown 13 (32.5%) 26 (39.4%) 39 (36.8%)
Age, mean (range) 59 (45, 69) 56 (46, 70) 58 (45, 70)
 BMI, mean (range) 28.5 (22.0, 35.4) 27.4 (21.5, 36.1) 28.1 (21.5, 36.1)
 Follow-up time, median (range) 18 (2, 23) 19 (3, 24) 19 (2, 24)
  1. Abbreviations: KPS Karnofsky Performance Scale, BMI body mass index